Title of article
Chronic viral hepatitis
Author/Authors
Patrick Marcellin، نويسنده , , Nathalie Boyer، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2003
Pages
17
From page
259
To page
275
Abstract
Chronic viral hepatitis is a common disease. More than 500 million people have chronic viral hepatitis worldwide. These diseases are due to chronic infection with hepatitis B virus, hepatitis D virus or hepatitis C virus. Chronic viral hepatitis is responsible for severe complications: cirrhosis and hepatocellular carcinoma, which are responsible for major morbidity and mortality worldwide. The prognosis of chronic viral hepatitis depends on the rate of progression of fibrosis, which varies widely from one patient to another. Some factors, such as gender, age, alcohol consumption and immune status, influence the progression of fibrosis. In recent years, treatment of chronic viral hepatitis has markedly improved—especially in chronic hepatitis C, with more than 50% of patients having a sustained response with the combination of pegylated interferon and ribavirin. Also, in chronic hepatitis B, new drugs are available, or being evaluated, and combination therapy could dramatically change future therapeutic strategies.
Keywords
cirrhosis , lamivudine , Genotypes , antiviral , Fibrosis , Interferon , Hepatocellular carcinoma , Ribavirin , pegylated interferon , adefovir
Journal title
Best Practice and Research Clinical Gastroenterology
Serial Year
2003
Journal title
Best Practice and Research Clinical Gastroenterology
Record number
466353
Link To Document